In new independent research reports released early this morning,
Capital Review released its latest key findings for all current
investors, traders, and shareholders of Lattice Semiconductor
Corporation (NASDAQ:LSCC), W&T Offshore, Inc. (NYSE:WTI),
Diplomat Pharmacy, Inc. (NYSE:DPLO), SYNNEX Corporation (NYSE:SNX),
Marchex, Inc. (NASDAQ:MCHX), and MEI Pharma, Inc. (NASDAQ:MEIP),
including updated fundamental summaries, consolidated fiscal
reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available
to readers at the links below.
LSCC DOWNLOAD:
http://Capital-Review.com/register/?so=LSCC WTI DOWNLOAD:
http://Capital-Review.com/register/?so=WTI DPLO DOWNLOAD:
http://Capital-Review.com/register/?so=DPLO SNX DOWNLOAD:
http://Capital-Review.com/register/?so=SNX MCHX DOWNLOAD:
http://Capital-Review.com/register/?so=MCHX MEIP DOWNLOAD:
http://Capital-Review.com/register/?so=MEIP
(You may have to copy and paste the link into your browser and
hit the [ENTER] key)
The new research reports from Capital Review,
available for free download at the links above, examine Lattice
Semiconductor Corporation (NASDAQ:LSCC), W&T Offshore, Inc.
(NYSE:WTI), Diplomat Pharmacy, Inc. (NYSE:DPLO), SYNNEX Corporation
(NYSE:SNX), Marchex, Inc. (NASDAQ:MCHX), and MEI Pharma, Inc.
(NASDAQ:MEIP) on a fundamental level and outlines the overall
demand for their products and services in addition to an in-depth
review of the business strategy, management discussion, and overall
direction going forward. Several excerpts from the recently
released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following
excerpts are not designed to be standalone summaries and as such,
important information may be missing from these samples. Please
download the entire research report, free of charge, to ensure you
are reading all relevant material information. Percentage
calculations are performed after rounding. All amounts in millions
(MM), except per share amounts.
-----------------------------------------
LATTICE SEMICONDUCTOR CORPORATION (LSCC) REPORT
OVERVIEW
Lattice Semiconductor's Recent Financial
Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Lattice Semiconductor reported revenue of
$95.98MM vs $95.27MM (up 0.75%) and analysts estimated basic
earnings per share -$0.05 vs -$0.06. For the twelve months ended
December 31st, 2018 vs December 31st, 2017, Lattice Semiconductor
reported revenue of $398.80MM vs $385.96MM (up 3.33%) and analysts
estimated basic earnings per share -$0.21 vs -$0.58. Analysts
expect earnings to be released on April 30th, 2019. The report will
be for the fiscal period ending March 31st, 2019. The reported EPS
for the same quarter last year was $0.01. The estimated EPS
forecast for the next fiscal year is $0.52 and is expected to
report on February 11th, 2020.
To read the full Lattice Semiconductor Corporation (LSCC)
report, download it here:
http://Capital-Review.com/register/?so=LSCC
-----------------------------------------
W&T OFFSHORE, INC. (WTI) REPORT
OVERVIEW
W&T Offshore's Recent Financial
Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, W&T Offshore reported revenue of
$143.42MM vs $129.10MM (up 11.09%) and analysts estimated basic
earnings per share $0.96 vs $0.17 (up 464.71%). For the twelve
months ended December 31st, 2018 vs December 31st, 2017, W&T
Offshore reported revenue of $580.71MM vs $487.10MM (up 19.22%) and
analysts estimated basic earnings per share $1.72 vs $0.56 (up
207.14%). Analysts expect earnings to be released on May 1st, 2019.
The report will be for the fiscal period ending March 31st, 2019.
Reported EPS for the same quarter last year was $0.19. The
estimated EPS forecast for the next fiscal year is $0.72 and is
expected to report on February 26th, 2020.
To read the full W&T Offshore, Inc. (WTI) report, download
it here:
http://Capital-Review.com/register/?so=WTI
-----------------------------------------
DIPLOMAT PHARMACY, INC. (DPLO) REPORT
OVERVIEW
Diplomat Pharmacy's Recent Financial
Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Diplomat Pharmacy reported revenue of
$1,360.63MM vs $1,155.07MM (up 17.80%) and analysts estimated basic
earnings per share -$4.01 vs $0.10. For the twelve months ended
December 31st, 2018 vs December 31st, 2017, Diplomat Pharmacy
reported revenue of $5,492.52MM vs $4,485.23MM (up 22.46%) and
analysts estimated basic earnings per share -$4.07 vs $0.23.
Analysts expect earnings to be released on May 6th, 2019. The
report will be for the fiscal period ending March 31st, 2019.
Reported EPS for the same quarter last year was $0.20. The
estimated EPS forecast for the next fiscal year is $0.40 and is
expected to report on March 20th, 2020.
To read the full Diplomat Pharmacy, Inc. (DPLO) report, download
it here:
http://Capital-Review.com/register/?so=DPLO
-----------------------------------------
SYNNEX CORPORATION (SNX) REPORT OVERVIEW
SYNNEX's Recent Financial Performance
For the three months ended November 30th, 2018
vs November 30th, 2017, SYNNEX reported revenue of $5,622.20MM vs
$5,311.88MM (up 5.84%) and basic earnings per share $2.52 vs $2.28
(up 10.53%). For the twelve months ended November 30th, 2018 vs
November 30th, 2017, SYNNEX reported revenue of $20,053.76MM vs
$17,045.70MM (up 17.65%) and analysts estimated basic earnings per
share $7.23 vs $7.54 (down 4.11%). Analysts expect earnings to be
released on June 27th, 2019. The report will be for the fiscal
period ending May 31st, 2019. The reported EPS for the same quarter
last year was $2.38. The estimated EPS forecast for the next fiscal
year is $12.61 and is expected to report on January 9th, 2020.
To read the full SYNNEX Corporation (SNX) report, download it
here:
http://Capital-Review.com/register/?so=SNX
-----------------------------------------
MARCHEX, INC. (MCHX) REPORT OVERVIEW
Marchex's Recent Financial Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Marchex reported revenue of $23.13MM vs
$21.85MM (up 5.88%) and analysts estimated basic earnings per share
-$0.01 vs -$0.02. For the twelve months ended December 31st, 2018
vs December 31st, 2017, Marchex reported revenue of $85.25MM vs
$90.29MM (down 5.58%) and analysts estimated basic earnings per
share -$0.06 vs -$0.15. Analysts expect earnings to be released on
May 2nd, 2019. The report will be for the fiscal period ending
March 31st, 2019. The reported EPS for the same quarter last year
was -$0.02. The estimated EPS forecast for the next fiscal year is
-$0.07 and is expected to report on February 12th, 2020.
To read the full Marchex, Inc. (MCHX) report, download it here:
http://Capital-Review.com/register/?so=MCHX
-----------------------------------------
MEI PHARMA, INC. (MEIP) REPORT OVERVIEW
MEI Pharma's Recent Financial Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, MEI Pharma reported revenue of $2.05MM vs
$0.36MM (up 472.07%) and analysts estimated basic earnings per
share $0.17 vs -$0.16. For the twelve months ended June 30th, 2018
vs June 30th, 2017, MEI Pharma reported revenue of $1.62MM vs
$23.25MM (down 93.02%) and analysts estimated basic earnings per
share -$0.97 vs $0.07. Analysts expect earnings to be released on
May 8th, 2019. The report will be for the fiscal period ending
March 31st, 2019. The reported EPS for the same quarter last year
was -$0.16. The estimated EPS forecast for the next fiscal year is
-$0.77 and is expected to report on August 29th, 2019.
To read the full MEI Pharma, Inc. (MEIP) report, download it
here:
http://Capital-Review.com/register/?so=MEIP
-----------------------------------------
ABOUT CAPITAL REVIEW
Capital Review is a nationally recognized
publisher of financial analysis, research reports, and exclusive
market reporting. Institutional investors, registered brokers,
professional traders, and personal investment advisers rely on
Capital Review to quantify public company valuations, discover
opportunity across asset classes, stay informed about market-moving
events, and read exclusive analysis of important material
developments. With 14 offices worldwide, Capital Review staffs and
manages certified and registered financial professionals, including
Chartered Financial Analyst® (CFA®) designation holders and FINRA®
BrokerCheck® certified individuals with current and valid CRD®
number designations, to enable continuous coverage of topics
relevant to its regular active reader base.
REGISTERED MEMBER STATUS
Capital Review's oversight and audit staff are
registered analysts, brokers, and/or financial advisers
("Registered Members") working within Equity Research, Media, and
Compliance departments. Capital Review's roster includes qualified
CFA® charterholders, licensed securities attorneys, and registered
FINRA® members holding duly issued CRD® numbers. Current licensed
status of several Registered Members at Capital Review have been
independently verified by an outside audit firm, including policy
and audit records duly executed by Registered Members. Complaints,
concerns, questions, or inquiries regarding this release should be
directed to Capital Review's Compliance department by Phone, at +1
(410) 280-7496, or by E-mail at compliance@Capital-Review.com.
LEGAL NOTICES
Information contained herein is not an offer or
solicitation to buy, hold, or sell any security. Capital Review,
Capital Review members, and/or Capital Review affiliates are not
responsible for any gains or losses that result from the opinions
expressed. Capital Review makes no representations as to the
completeness, accuracy, or timeliness of the material provided and
all materials are subject to change without notice. Capital Review
has not been compensated for the publication of this press release
by any of the above mentioned companies. Capital Review is not a
financial advisory firm, investment adviser, or broker-dealer, and
does not undertake any activities that would require such
registration. For our full disclaimer, disclosure, and terms of
service please visit our website.
Media Contact: Morena Zambada, Media Department
Office: +1 (410) 280-7496 E-mail: media@Capital-Review.com
© 2019 Capital Review. All Rights Reserved. For
republishing permissions, please contact a partner network manager
at partnership@Capital-Review.com.
CFA® and Chartered Financial Analyst® are registered
trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks
owned by Financial Industry Regulatory Authority, Inc.
Marchex (NASDAQ:MCHX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Marchex (NASDAQ:MCHX)
Historical Stock Chart
From Sep 2023 to Sep 2024